Table 3 Adverse events prior to week 14
Adverse Event Outcome | Calcium acetate (N = 46) | Placebo (N = 64) | P-value |
|---|---|---|---|
Patients with any adverse event | 30 (65.2%) | 42 (65.6%) | 0.96 |
Any adverse event, rate (per subject per visit) | 0.42 | 0.57 | 0.46 |
Patients with related adverse event | 5 (10.9%) | 9 (14.1%) | 0.16 |
Related adverse event, rate (per subject per visit) | 0.39 | 0.36 | 0.84 |
Adverse events related to medication by organ system class | |||
Cardiac disorders | 0 | 1 (1.6%) | |
Gastrointestinal disorders | 3 (6.5%) | 6 (9.4%) | |
General disorders | 1 (2.2%) | 0 | |
Investigations | 1 (2.2%) | 0 | |
Metabolism and nutrition disorders | 2 (4.3%) | 1 (1.6%) | |
Musculoskeletal and connective tissue disorders | 0 | 1 (1.6%) | |
Skin and subcutaneous tissue disorders | 0 | 1 (1.6%) | |
Vascular disorders | 0 | 1 (1.6%) |